Novel diagnostic, prognostic and treatment tool for CRC and lymphoma. Antigenic properties provide potential vaccine for CRC and lymphoma to inhibit metastasis.

Novel diagnostic, prognostic and treatment tool for CRC and lymphoma. Antigenic properties provide potential vaccine for CRC and lymphoma to inhibit metastasis. Potential for different VICKZ isoforms to regulate different RNA targets. Oncofetal VICKZ protein is absent in almost all normal adult tissue; it is highly specific to neoplastic cells. 

Correlation established between elevated expression of VICKZ proteins and colorectal cancer (CRC) and germinal center B-cell derived lymphomas

Highlights

• Level of VICKZ protein expression proven to establish level of metastasis.
• Provides for targeted diagnosis, prognosis and treatment of colorectal (CRC) and lymphoid cancers.
• Research expands on previous knowledge base of expression role of VICKZ proteins in different types of carcinomas.

Our Innovation (facts and advantages)

• Novel diagnostic, prognostic and treatment tool for CRC and lymphoma.
• Antigenic properties provide potential vaccine for CRC and lymphoma to inhibit metastasis.
• Potential for different VICKZ isoforms to regulate different RNA targets.
• Oncofetal VICKZ protein is absent in almost all normal adult tissue; it is highly specific to neoplastic cells 

The Opportunity

• Diagnostic and prognostic refinement provides enhanced treatment specificity.
• Potential vaccine provides viable alternative to costly chemotherapy protocols (up to $9,000 per month).
• Enhances the patients quality of life by eliminating chemotherapy-related side effects.

Development milestones

• Initial hypothesis proven / Mouse models next step
• For CRC, hypothesis proven in archived samples and cultured cells; research continues in retrospective tissue microarray studies and occult blood
• Testing inhibition of VICKZ function in vivo through the use of mouse models
• Testing diagnostic and prognostic value of VICKZ expression in different lymphoma subtypes
• Developing and testing a vaccine against CRC and GC B-cell derived lymphomas based on targeting VICKZ-expressing cells

 Market size: $20.5B

Early Stage

Patent pending